D8A3D7E7-BDC0-42FF-B451-E25F472E8612
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 7.391590013140604
- age_years
- 72
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.581
- IL6_JAK_STAT3_SIGNALING+0.579
- ANGIOGENESIS+0.554
- ALLOGRAFT_REJECTION+0.532
- MYC_TARGETS_V1+0.530
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.529
- HYPOXIA+0.525
- INFLAMMATORY_RESPONSE+0.519
- INTERFERON_GAMMA_RESPONSE+0.499
- MTORC1_SIGNALING+0.489
Top 10 suppressed
- KRAS_SIGNALING_DN-0.433
- SPERMATOGENESIS-0.275
- PANCREAS_BETA_CELLS-0.240
- HEDGEHOG_SIGNALING-0.128
- MYOGENESIS-0.119
- BILE_ACID_METABOLISM-0.053
- ESTROGEN_RESPONSE_EARLY-0.051
- MITOTIC_SPINDLE-0.010
- APICAL_SURFACE-0.004
- ESTROGEN_RESPONSE_LATE+0.019
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 9BFF7746-9003-4941-9590-0B813E00B326 | — | — | 0.983 |
| 2 | F9EB85A8-8E6D-44C0-8C59-50B1DB4E652B | — | — | 0.979 |
| 3 | F9A39954-57EB-4A3F-97A0-1801B08BBD53 | — | — | 0.979 |
| 4 | 4B93A447-E626-4040-9BA0-1EEAB3764C6B | — | — | 0.979 |
| 5 | 825AC0F8-4D16-4109-AA6A-4648934E3C35 | — | — | 0.978 |
| 6 | 0E66EFB0-712B-4A52-8F75-A37F030CABEF | — | — | 0.977 |
| 7 | 4A54E284-9902-4E4C-A5BC-1BF144106EA3 | — | — | 0.976 |
| 8 | SRR934913 | — | — | 0.976 |
| 9 | 3027792F-79B6-4729-9452-C4A72A7C4686 | — | — | 0.975 |
| 10 | CE7A3262-C48A-43BF-941C-9D2482B9CACD | — | — | 0.974 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.581 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.579 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.554 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.532 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.530 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.529 | Inavolisib | — uncovered |
| HYPOXIA | 0.525 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.519 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.499 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.489 | Inavolisib | — uncovered |
| APOPTOSIS | 0.469 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.450 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.450 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.445 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.431 | Idelalisib | — uncovered |
| COAGULATION | 0.419 | Binimetinib | — uncovered |
| PROTEIN_SECRETION | 0.405 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.404 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.401 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.396 | Idelalisib | — uncovered |